



Trillium
Gift of Life
Network

Ontario's Adult Referral and Listing Criteria for Liver Transplantation

Version 4.0

Trillium Gift of Life Network

Ontario's Adult Referral & Listing Criteria for Liver Transplantation

PATIENT REFERRAL CRITERIA:

The patient referral criteria are criteria which a Health Care Provider would utilize to refer a patient to a transplant centre for assessment. The criteria identified below are the currently agreed upon conditions for which a patient should be considered for referral for liver transplant assessment.

- 1) **Chronic Liver Disease:** Referral for adult liver transplantation should be considered for patients with decompensated chronic liver disease. Such patients generally have one or more of the following:
 - End-stage of chronic liver disease with hepatic decompensation
 - Ascites or complications thereof such as hepatic hydrothorax and (resolved) spontaneous bacterial peritonitis, jaundice, hepatic encephalopathy or portal hypertensive GI bleed. These patients will typically have a Sodium Model of End-stage Liver Disease score (Na MELD) score of greater than or equal to 11 or a Child-Pugh B score of greater than or equal to 7;
 - Other Complications of End-stage Liver Disease or Portal Hypertension such as
 - Hepatopulmonary syndrome (HPS);
 - Hepatocellular carcinoma (HCC).
- 2) **Fulminant hepatic failure**
- 3) **Metabolic Disorders:** Referral for adult liver transplantation may also be considered for patients with metabolic disorders of hepatic origin. This may include conditions such as hereditary transthyretin amyloidosis, hyperoxaluria type I and others.

Early referral is essential to allow the patient to be evaluated and to survive (in a condition that still allows major surgery) until a suitable organ becomes available.

PATIENT LISTING INDICATIONS:

Each patient is assessed individually for his/her suitability for liver transplantation by one of the two provincial liver transplant programs (London or Toronto). The criteria identified below are the currently agreed upon general and specific conditions for which a patient may be eligible to be waitlisted for liver transplantation in Ontario.

- 1) **General:** Listing for liver transplantation may be considered for patients if the following requirements are met:
 - Therapeutic options, other than liver transplantation, have been exhausted;
 - Absence of obvious contraindication for transplant; and,
 - Expected 5 year survival \geq 60% (co-morbidity, compliance).
- 2) **End-Stage Chronic Liver Disease:** Listing for liver transplantation may be considered for patients with decompensated cirrhosis with a Sodium MELD (Na MELD*) score of greater or equal to 15. Patients with Na MELD scores of 11 - 15 (or, under exceptional circumstances, less) may be considered only with the presence of factor(s) indicating poor prognosis that is/are not adequately captured by their Na MELD score (e.g. recurrent cholangitis, refractory ascites).

* Na MELD is a scoring system for assessing the severity of chronic liver disease; the higher the score, the more severe the liver disease and the lower the patient's 90 day survival without a liver transplant.

- 3) **Hepatocellular Carcinoma (HCC):** Patients with hepatocellular carcinoma may be considered for liver transplantation. However, they must be carefully selected to minimize the chance of recurrence after surgery. Of note, exception points for allocation purposes will be granted only if the HCC meets the following criteria: one HCC nodule greater than or equal to 2cm or multiple HCC nodules greater than or equal to 1cm or one HCC nodule greater than 1cm and less than or equal to 2cm that cannot be treated by intent to cure other than liver transplantation or any recurrent HCC nodule greater than or equal to 1cm. In addition to meeting one of the aforementioned criteria patients must meet all of the following criteria to be granted exception points for allocation: Total Tumour Volume (TTV) less than or equal to 145cm³ and Alpha Fetoprotein (AFP) less than or equal to 1,000, diagnostic imaging for HCC (if imaging not diagnostic than a biopsy is required), no evidence of vascular invasion or extrahepatic spread and no HCC mixed with predominance of cholangiocarcinoma features on histology.

HCC patients not fulfilling the specified criteria (outlined above) do not receive exception points but can be actively listed as per their calculated SMC.

- 4) **Fulminant Hepatic Failure:** Patients with fulminant hepatic failure may be considered for liver transplantation if they meet the Kings College Criteria or other validated criteria and have no contraindication (see below) for transplant.
- 5) **Metabolic Diseases:** Liver transplantation may be offered as therapy for patients with certain metabolic diseases of hepatic origin (e.g. hereditary transthyretin amyloidosis, Maple Syrup Urine Disease, hyperoxaluria type I, etc.).
- 6) **Other Conditions:** Selected patients with certain rare conditions may be considered for liver transplantation. Such conditions may include:
- Selected cholangiocarcinoma (within the Mayo Clinic protocol)
 - Selected neuroendocrine liver tumours
 - Fibrolamellar HCCs
 - Selected hepatoblastomas

PATIENT LISTING CONTRAINDICATIONS:

The contraindications for liver transplantation identified below are the currently agreed upon conditions in which the presence of one or more would result in the patient not being eligible to be waitlisted for liver transplantation in Ontario.

- 1) **Co-Morbidities:** Patients with any co-morbidity that decreases the likelihood of surviving 5 years post-transplant to below 50% or for whom the peri-operative risk is deemed unacceptably high are not candidates for liver transplantation.
- 2) **Nutritional State:** For a patient with a calculated body mass index (BMI) [estimated dry weight (kg) divided by height (cm)] that exceeds 40 kg/m², liver transplantation is a relative contraindication due to excessive morbidity and potential excess mortality. For patients with a BMI > 45 kg/m², liver transplantation should be contraindicated except in exceptional circumstances.

For a patient with a body mass index (BMI) < 18.5 kg/m², liver transplantation is a relative contraindication, and aggressive nutritional support should be implemented.

- 3) **Infections:** Patients are not candidates for liver transplantation if they display the following:
 - Active or uncontrolled extrahepatic infection (including sepsis)
 - Uncontrolled HIV infection (i.e. detectable viral load and/or CD4 count <100) or AIDS.

- 4) **Malignancy:** Patients with extrahepatic malignancy are not candidates for liver transplantation. In general, patients must be cancer free for at least 2 - 5 years after curative therapy, depending on the cancer type. This may be assessed on an individual patient basis depending on the type and stage of the tumour.

- 5) **Vascular Abnormalities:** Patients with extensive thrombosis of the Portal Vein, Superior Mesenteric Vein and Splenic Vein, or other extensive vascular anomalies or pathologies precluding sufficient revascularization of the graft are not candidates for liver transplantation.

- 6) **Psychosocial Considerations:** Patients who display any of the following are not candidates for liver transplantation:
 - Unstable psychiatric disorder, especially one likely to interfere with compliance;
 - Any alcohol and/or illicit drug misuse within six months;
 - i. For patients with alcohol associated liver disease: inability to absolutely abstain from alcohol and/or illicit drug use for six months
 - Previous documentation or current unwillingness or inability to follow the advice of health professionals;
 - Social support/compliance issues prohibiting adherence to post-operative medications and/or follow-up care.

Version Control:

Name of Document	Ontario's Adult Referral and Listing Criteria for Liver Transplantation
Version 1.0	Created November 2012
Version 2.0	Updated July 2015
Version 3.0	Updated November 2017
Version 4.0	Updated November 2018
Recommended Next Review	November 2020
Approved By	Provincial Liver and Small Bowel Working Group Transplant Steering Committee